Abstract 6109
Background
Brachytherapy unit of the Catalan Institute of Oncology (ICO) is a referral centre on Brachytherapy treatments for Catalonia. A total of 700 treatments are performed per year, mainly in gynaecological, prostate and breast cancer. For the last 5 years, intraoperative brachytherapy has been promoted to be done in other centres, outside in the region. That implies that specialist professionals from our cancer centre go to operating rooms in different hospitals. The surgery process is done outside in the Paediatric hospital and the Brachytherapy treatment is realised in the cancer centre ICO. Aim: to describe nursing activities and roles to facilitate the Brachytherapy treatment done outside and in collaboration with other hospitals.
Methods
Descriptive study on cases done last year 2018 with patients outside ICO, most common type of treatments were sarcoma in paediatric tumours, patients with recurrence disease undergoing salvage after surgery or recurrence for breast cancer. Procedure: When a case arrived to the specialist they confirm indication and initiate the process; On the day of surgery, a medical and nurses team from the brachytherapy unit moves to hospital They perform the placement of internal applicators at the time of surgery. Later next 12-24h patient moves to brachytherapy unit to undergo the protocol of radiation. Once the brachytherapy treatment is finished, patient is discharged. The nursing staff of brachytherapy unit takes charge of plan care during treatment.
Results
Pediatric brachytherapy in oncological patient: experience of collaboration of 5 years with 10 patients treated. A total of 53 breast brachytherapy has been done intraoperative: consolidated collaboration, generates around 3 monthly patients from different medical centers. A total of 10 cases done for salvage brachytherapy in patients with recurrence after surgery.
Conclusions
Intraoperative brachytherapy improves the patient’s accessibility to highly specialized treatments. The procedure and development of this treatment in different hospitals improves results in some tumours, reduces the overall time of treatment. Nursing staff has knowledge and skills for the management and care of this patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2171 - CCND1 Amplification Contributes to Immunosuppression in Head and Neck Squamous Cell Carcinoma and the Association with a Poor Response to Immune Checkpoint Inhibitors
Presenter: Chloe Huang
Session: Poster Display session 3
Resources:
Abstract
2624 - Efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer patients with sensitive genes mutation
Presenter: Hui-Juan Cui
Session: Poster Display session 3
Resources:
Abstract
3494 - Neutrophil to Lymphocyte Ratio (NLR) kinetics as predictors of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (NSCLC) patients treated with nivolumab (N).
Presenter: Audrey Simonaggio
Session: Poster Display session 3
Resources:
Abstract
3964 - Predictive markers of checkpoint inhibitor activity in adult metastatic solid tumours
Presenter: Alexandra Pender
Session: Poster Display session 3
Resources:
Abstract
3041 - Blood-based TMB (bTMB) correlates with tissue-based TMB (tTMB) in a multi-cancer Phase I IO Cohort
Presenter: Daniel Araujo
Session: Poster Display session 3
Resources:
Abstract
3910 - Analysis of Molecular Profile Complexities for Immunotherapy Decision Support
Presenter: Robert Dóczi
Session: Poster Display session 3
Resources:
Abstract
4836 - The Role of Tumor Neoantigens in the Differential Response to Immunotherapy (IO) in EGFR and BRAF Mutated Lung Cancers - Quantity or Quality?
Presenter: Katrina Case
Session: Poster Display session 3
Resources:
Abstract
1929 - Impact of previous corticosteroid (CS) exposure on efficacy of Programmed Cell Death-(Ligand) 1 blockade in patients with advanced Non-Small-Cell Lung Cancer (NSCLC): a single Center retrospective analysis
Presenter: Fabrizio Nelli
Session: Poster Display session 3
Resources:
Abstract
2601 - Comparison 18F-FDG-PET/CT criteria for prediction of therapy response and clinical outcome in patients with metastatic melanoma treated with Ipilimumab and PD-1 inhibitors
Presenter: Sabrina Vari
Session: Poster Display session 3
Resources:
Abstract
3628 - Predictive model for survival in advanced non-small-cell lung cancer (NSCLC) treated with frontline pembrolizumab
Presenter: Xabier Mielgo Rubio
Session: Poster Display session 3
Resources:
Abstract